Papers 8

  1. Optimisation of real-time quantitative RT-PCR for the evaluation of non-viral mediated gene transfer to the airways.
    Rose AC et al., Gene Ther. 2002 Oct;9(19):1312-20.
  2. Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor 1alpha promoter.
    Gill DR et al., Gene Ther. 2001 Oct;8(20):1539-46.
  3. Inflammation in cystic fibrosis airways: relationship to increased bacterial adherence.
    Scheid P et al., Eur Respir J. 2001 Jan;17(1):27-35.
  4. Chloride secretion in the trachea of null cystic fibrosis mice: the effects of transfection with pTrial10-CFTR2.
    MacVinish LJ et al., J Physiol. 1997 Mar 15;499 ( Pt 3):677-87.
  5. Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy.
    Hyde SC et al., Nature. 1993 Mar 18;362(6417):250-5.
  6. A second dose of a CFTR cDNA-liposome complex is as effective as the first dose in restoring cAMP-dependent chloride secretion to null CF mice trachea.
    Goddard CA et al., Gene Ther. 1997 Nov;4(11):1231-6.
  7. A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis.
    Gill DR et al., Gene Ther. 1997 Mar;4(3):199-209.
  8. Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis.
    Hyde SC et al., Gene Ther. 2000 Jul;7(13):1156-65.


A frozen vial of GL67A (left) and a frozen vial of pGM169 plasmid DNA (right)


Proposed 3D model of the CFTR protein.